Newer gene editing technologies toward HIV gene therapy

Area of Science:

• Genetics
• Molecular Biology
• Virology

Background:

• Highly active antiretroviral therapy (HAART) manages HIV but requires lifelong treatment.
• The
• Berlin patient
• case suggests potential for HIV eradication via CCR5-negative bone marrow transplant.
• Advances in understanding DNA repair and bacterial defense mechanisms enable precise gene editing.

Purpose of the Study:

• To review novel gene-editing technologies for HIV therapy.
• To discuss the applications, limitations, and future prospects of these strategies.
• To explore alternatives to lifelong antiretroviral therapy for HIV infection.

Main Methods:

• Review of emerging gene-editing technologies: Homing Endonuclease, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALEN), and CRISPR/Cas9.
• Comparison of CRISPR/Cas9 mechanism (RNA-guided DNA cleavage) with ZFN and TALEN (DNA-binding motifs fused to endonucleases).
• Analysis of permanent gene disruption capabilities versus transient gene silencing methods like RNA interference.

Main Results:

• Four novel gene-editing technologies enable site-specific DNA modification.
• CRISPR/Cas9 system offers a precise and potentially permanent method for gene editing.
• These technologies allow for permanent disruption of targeted genes after a single treatment, unlike RNA interference.

Conclusions:

• Genome engineering presents a promising avenue for a curative HIV therapy.
• CRISPR/Cas9 and similar technologies offer a potential one-time treatment for HIV.
• Further research is needed to address the applications, limitations, and future prospects of gene editing in HIV therapy.